A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

Recruiting now · Phase 1/Phase 2

Conditions studied: Relapsed/Refractory Small Cell Lung Cancer

In brief

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer

Key facts

Study ID

NCT07325136

Run by

Bristol-Myers Squibb

People needed

240

Starts

2026-02-03

Expected to finish

2029-04-24

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
• Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
• In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.

You may not qualify if…

• Participants must not have any untreated CNS metastases.
• Participants must not have an active, known or suspected autoimmune disease.
• Participants must not have had a prior organ or tissue allograft.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Karmanos Cancer Institute — Detroit, Michigan, United States (enrolling)
• Duke Cancer Institute — Durham, North Carolina, United States (enrolling)
• University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States (enrolling)
• SCRI Oncology Partners — Nashville, Tennessee, United States (enrolling)
• Istituto Clinico Humanitas — Rozzano, Milano, Italy (enrolling)
• Oncohelp Medical Center — Timișoara, Timiș County, Romania (enrolling)
• Local Institution - 0003 — Craiova, Romania
• Local Institution - 0026 — Buffalo, New York, United States
• Local Institution - 0020 — Hirakata, Osaka, Japan
• Local Institution - 0018 — Chuo-ku, Tokyo, Japan
• Local Institution - 0009 — Madrid, Spain
• Local Institution - 0028 — Shanghai Shi, Shanghai Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.